Intera Oncology

Executive Summary

Intera Oncology is a private medical device company based in Cambridge, Massachusetts, dedicated to improving outcomes for patients with colorectal cancer and intrahepatic cholangiocarcinoma that has metastasized to the liver. The company's core product is the Intera 3000 Hepatic Artery Infusion (HAI) Pump, which delivers chemotherapy directly to liver tumors, potentially enhancing efficacy while reducing systemic side effects. Founded in 2020, Intera Oncology is still in the early stages of commercialization and regulatory approval. The HAI pump addresses a significant unmet need, as liver metastases are common in colorectal cancer and bile duct cancer, and localized chemotherapy offers a promising approach. However, the company faces challenges including regulatory hurdles, competition from alternative therapies, and the need to demonstrate clinical and economic value. With a focused strategy and a differentiated product, Intera Oncology has the potential to carve out a niche in the oncology device market, but its success hinges on successful clinical trials, FDA clearance, and adoption by major cancer centers.

Upcoming Catalysts (preview)

• Q3 2026Initial FDA Submission for the Intera 3000 HAI Pump60% success
• TBDPublication of Pivotal Clinical Trial Results50% success
• TBDStrategic Partnership or Distribution Agreement40% success